Entry and submarket concentration: empirical evidence from the pharmaceutical industry
The paper investigates the decisions of companies to enter new submarkets, analyzing the relationship between submarket concentration and entry through the explanatory power of submarkets. The relationship is analyzed both at the aggregate level for all countries and both at the country-specific level using a pharmaceutical company dataset gathered in seven countries in the 1987-1998 period. A Bayesian panel probit model enables us to measure entry into a new submarket using the lagged dependent variable to incorporate potential state persistence. The results obtained at the submarket level indicate a negative correlation between concentration and entry by diversification, although previous literature at market level has indicated conflicting results for the same relationship.
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Volume (Year): 2012/3 (2012)
Issue (Month): 3 ()
|Contact details of provider:|| Web page: http://www.francoangeli.it/riviste/sommario.asp?IDRivista=13|
|Order Information:|| Web: http://www.francoangeli.it/riviste/Elenco_Prodotti.aspx?startCode=DC Email: |
When requesting a correction, please mention this item's handle: RePEc:fan:polipo:v:html10.3280/poli2012-003001. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Angelo Ventriglia)
If references are entirely missing, you can add them using this form.